Therapeutics and DNA methylation inhibitors

Shyamala C. Navada

doi:10.1016/B978-0-12-823928-5.00014-1

Therapeutics and DNA methylation inhibitors

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Dysregulation of cellular epigenetic machinery is linked to the pathogenesis of a number of malignancies and has been studied extensively in myelodysplastic syndromes and acute myeloid leukemia. Alteration of DNA methylation in cancer cells results in transcriptional silencing of tumor suppressor genes. DNA methyltransferase inhibitors, such as azacitidine and decitabine, have been used to reexpress these genes and have demonstrated therapeutic benefits in both benign and malignant diseases. In this chapter, we discuss the clinical application of demethylating agents, the data that have led to their approval in hematologic diseases, and the future potential uses of these agents, both alone and in combination.

Original language	English
Title of host publication	Medical Epigenetics
Publisher	Elsevier
Pages	585-595
Number of pages	11
ISBN (Electronic)	9780128239285
DOIs	https://doi.org/10.1016/B978-0-12-823928-5.00014-1
State	Published - 1 Jan 2021

Keywords

Acute myeloid leukemia
Azacitidine
DNA methyltransferase inhibitors
Decitabine
Hypomethylating agents
Myelodysplastic syndromes

Access to Document

10.1016/B978-0-12-823928-5.00014-1

Cite this

@inbook{4f816db2a1ef4555a9bd2b16006d937f,

title = "Therapeutics and DNA methylation inhibitors",

abstract = "Dysregulation of cellular epigenetic machinery is linked to the pathogenesis of a number of malignancies and has been studied extensively in myelodysplastic syndromes and acute myeloid leukemia. Alteration of DNA methylation in cancer cells results in transcriptional silencing of tumor suppressor genes. DNA methyltransferase inhibitors, such as azacitidine and decitabine, have been used to reexpress these genes and have demonstrated therapeutic benefits in both benign and malignant diseases. In this chapter, we discuss the clinical application of demethylating agents, the data that have led to their approval in hematologic diseases, and the future potential uses of these agents, both alone and in combination.",

keywords = "Acute myeloid leukemia, Azacitidine, DNA methyltransferase inhibitors, Decitabine, Hypomethylating agents, Myelodysplastic syndromes",

author = "Navada, {Shyamala C.}",

year = "2021",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-823928-5.00014-1",

language = "English",

pages = "585--595",

booktitle = "Medical Epigenetics",

publisher = "Elsevier",

address = "Netherlands",

}

TY - CHAP

T1 - Therapeutics and DNA methylation inhibitors

AU - Navada, Shyamala C.

PY - 2021/1/1

Y1 - 2021/1/1

N2 - Dysregulation of cellular epigenetic machinery is linked to the pathogenesis of a number of malignancies and has been studied extensively in myelodysplastic syndromes and acute myeloid leukemia. Alteration of DNA methylation in cancer cells results in transcriptional silencing of tumor suppressor genes. DNA methyltransferase inhibitors, such as azacitidine and decitabine, have been used to reexpress these genes and have demonstrated therapeutic benefits in both benign and malignant diseases. In this chapter, we discuss the clinical application of demethylating agents, the data that have led to their approval in hematologic diseases, and the future potential uses of these agents, both alone and in combination.

AB - Dysregulation of cellular epigenetic machinery is linked to the pathogenesis of a number of malignancies and has been studied extensively in myelodysplastic syndromes and acute myeloid leukemia. Alteration of DNA methylation in cancer cells results in transcriptional silencing of tumor suppressor genes. DNA methyltransferase inhibitors, such as azacitidine and decitabine, have been used to reexpress these genes and have demonstrated therapeutic benefits in both benign and malignant diseases. In this chapter, we discuss the clinical application of demethylating agents, the data that have led to their approval in hematologic diseases, and the future potential uses of these agents, both alone and in combination.

KW - Acute myeloid leukemia

KW - Azacitidine

KW - DNA methyltransferase inhibitors

KW - Decitabine

KW - Hypomethylating agents

KW - Myelodysplastic syndromes

UR - http://www.scopus.com/inward/record.url?scp=85128020314&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-823928-5.00014-1

DO - 10.1016/B978-0-12-823928-5.00014-1

M3 - Chapter

AN - SCOPUS:85128020314

SP - 585

EP - 595

BT - Medical Epigenetics

PB - Elsevier

ER -

Therapeutics and DNA methylation inhibitors

Abstract

Keywords

Access to Document

Fingerprint

Cite this